Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

Journal of the American College of Cardiology

Volumn 52, Issue 7, 2008, Pages 512-517

  Ndrepepa, Gjin ^a   Mehilli, Julinda ^a   Schulz, Stefanie ^a   Iijima, Raisuke ^a   Keta, Dritan ^a   Byrne, Robert A ^a   Pache, Jürgen ^a   Seyfarth, Melchior ^a   Schömig, Albert ^a,b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

acute coronary syndrome; mortality; percutaneous coronary intervention; TIMI flow grade

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIAC PATIENT; CONFIDENCE INTERVAL; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; STATISTICAL MODEL; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD FLOW VELOCITY; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MYOCARDIUM; ODDS RATIO; PERFUSION; PERICARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; STROKE VOLUME; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 48449105426     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.05.009     Document Type: Article

References (15)

1. TIMI Study Group. Definitions used in TIMI trials. http://www.timi.org Accessed January 20, 2008
2. Simes R.J., Topol E.J., Holmes Jr. D.R., et al., GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 91 (1995) 1923-1928
3. Wall T.C., Califf R.M., George B.S., et al. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. J Am Coll Cardiol 19 (1992) 482-489
4. Brodie B.R., Stuckey T.D., Hansen C., and Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 85 (2000) 13-18
5. Karagounis L., Sorensen S.G., Menlove R.L., Moreno F., and Anderson J.L. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 19 (1992) 1-10
6. Anderson J.L., Karagounis L.A., Becker L.C., Sorensen S.G., and Menlove R.L. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 87 (1993) 1829-1839
7. Anderson J.L., Karagounis L.A., and Califf R.M. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 78 (1996) 1-8
8. Lenderink T., Simoons M.L., Van Es G.A., Van de Werf F., Verstraete M., Arnold A.E., and The European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 92 (1995) 1110-1116
9. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 97 (1998) 1549-1556
10. Stone G.W., Grines C.L., Cox D.A., et al., Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
11. Stone G.W., Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 (2001) 636-641
12. Mehta R.H., Harjai K.J., Cox D., et al., Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1739-1746
13. Kerensky R.A., Wade M., Deedwania P., Boden W.E., Pepine C.J., and Veterans Affairs Non-Q-Wave Infarction Strategies in-Hospital (VANQWISH) Trial Investigators. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 39 (2002) 1456-1463
14. De Luca G., Ernst N., Zijlstra F., et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 43 (2004) 1363-1367
15. Ndrepepa G., Kastrati A., Schwaiger M., et al. Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. J Nucl Med 46 (2005) 1782-1788